title: Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia.
abstract: Pneumonia is associated with an extremely high mortality rate in patients of late elderly age. Piperacillin/tazobactam and carbapenems are drugs of first choice for hospitalized patients with potentially resistant bacteria. We compared the efficacy and safety of piperacillin/tazobactam and biapenem. Among elderly patients with nursing- and healthcare-associated pneumonia, we extracted 53 patients treated with piperacillin/tazobactam and 53 patients treated with biapenem who were matched for sex, age, and severity of pneumonia. The average age was more than 80 years; most of the patients were middle- to oldest old in age. Although clinical efficacy was equally good, patients in the piperacillin/tazobactam group achieved significantly faster improvements on chest X-ray and body temperature on day 7. However, in the piperacillin/tazobactam group, nephrotoxicity frequently led to a need for a reduction in the dose or complete discontinuation of treatment. The average age of patients who developed significant nephrotoxicity was high, at 83.2 years. The biapenem group exhibited significantly better continuation of treatment than the piperacillin/tazobactam group. Toxicity profiles were different between the two groups. Hepatic toxicity was significantly higher in the biapenem group, whereas nephrotoxicity was significantly more common in the piperacillin/tazobactam group. Rate of decrease in bacteria was equally good between the two groups. Providing careful follow-up and conducting more detailed examinations, including studies to determine optimal dose and timing of administration, are necessary for the treatment of late elderly patients with numerous underlying diseases and potential organ dysfunctions.
authors: Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya cho, Izumo, Shimane, Japan.
authors: Fumi
authors: F
authors: Karino
authors: Kiyotaka
authors: K
authors: Miura
authors: Hiroshi
authors: H
authors: Fuchita
authors: Naoya
authors: N
authors: Koba
authors: Emiko
authors: E
authors: Nishikawa
authors: Takamasa
authors: T
authors: Hotta
authors: Tamio
authors: T
authors: Okimoto
authors: Shinichi
authors: S
authors: Iwamoto
authors: Yukari
authors: Y
authors: Tsubata
authors: Mitsuhiro
authors: M
authors: Tada
authors: Shunichi
authors: S
authors: Hamaguchi
authors: Takeshi
authors: T
authors: Honda
authors: Miki
authors: M
authors: Ohe
authors: Akihisa
authors: A
authors: Sutani
authors: Takashige
authors: T
authors: Kuraki
authors: Hiroyasu
authors: H
authors: Takeyama
authors: Takeshi
authors: T
authors: Isobe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000009:adverse effects / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D012189:Retrospective Studies; D013183:Sputum / Q000382:microbiology; D013845:Thienamycins / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; C065257:biapenem